Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

171
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
171
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

134
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
134

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extrapleural Pneumonectomy for Treatment of Pulmonary Adenoid Cystic Carcinoma.

Annals of thoracic surgery short reports·2025
Same author

Multidisciplinary management of a complex case of postesophagectomy tracheoesophageal fistula.

JTCVS techniques·2025
Same author

Surgical approaches for thymectomy: a narrative review.

Mediastinum (Hong Kong, China)·2025
Same author

Gastropericardial Fistula After Collis Gastroplasty and Nissen Fundoplication.

Annals of thoracic surgery short reports·2025
Same author

Esophageal perforation after anterior cervical spine surgery.

JTCVS techniques·2024
Same author

A nationwide analysis of disparities in guideline-concordant care in American Indians and Alaska Natives with stage I non-small cell lung cancer.

Journal of thoracic disease·2023

Related Experiment Video

Updated: May 23, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.2K

Adjuvant Chemotherapy in Colon Cancer: Simple is Better… Less is More.

Prasad Narayanan1, Shyam Aggarwal2, Manish Singhal3

  • 1Department of Medical Oncology, Cytecare Hospital, Bengaluru, Karnataka, India.

South Asian Journal of Cancer
|March 10, 2025
PubMed
Summary
This summary is machine-generated.

Adjuvant therapy improves outcomes for colorectal cancer (CRC) patients. Shorter regimens like CAPOX and SOX offer alternatives to standard FOLFOX, with personalized selection improving treatment efficacy.

Keywords:
MRDctDNAdrug metabolismgeriatric patientsoverall survivaltoxicity

More Related Videos

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

199

Related Experiment Videos

Last Updated: May 23, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.2K
Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
12:37

Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS

Published on: September 11, 2012

46.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

199

Area of Science:

  • Oncology
  • Medical Oncology
  • Gastroenterology

Background:

  • Adjuvant therapy significantly benefits patients with colorectal cancer (CRC).
  • Current standard of care involves 6 months of FOLFOX, but shorter regimens like CAPOX and SOX are emerging.
  • Clinical trials such as SCOT, TOSCA, Alliance/SWOG80702, IDEA, ACHIEVE, and HORG are evaluating these treatments.

Purpose of the Study:

  • To review current adjuvant therapy options for colorectal cancer.
  • To discuss the role of patient preferences and novel biomarkers in treatment selection.
  • To highlight considerations for geriatric CRC patients.

Main Methods:

  • Review of key clinical trials comparing adjuvant chemotherapy regimens for CRC.
  • Analysis of factors influencing treatment decisions, including patient preferences and molecular markers.
  • Consideration of specific challenges in managing elderly patients with CRC.

Main Results:

  • Shorter adjuvant chemotherapy regimens (CAPOX, SOX) are viable alternatives to standard FOLFOX.
  • Patient selection can be optimized using molecular biomarkers and circulating tumor DNA (ctDNA) for minimal residual disease (MRD) monitoring.
  • Geriatric patients require special attention due to comorbidities, polypharmacy, and mobility issues.

Conclusions:

  • Optimizing adjuvant therapy for colorectal cancer involves balancing efficacy with patient-specific factors.
  • Personalized treatment selection, incorporating biomarkers and patient preferences, is crucial for improving outcomes.
  • Tailored management strategies are essential for geriatric populations undergoing CRC treatment.